Eligible patients aged 18-75 years received indapamide 15 mg , ramipril 10 mg ( or irbesartan 300 mg ) , and amlodipine 10 mg daily for 4 weeks to confirm treatment resistance by ambulatory blood pressure monitoring before randomisation .